How Long Has Ozempic Been Out? The Complete Timeline from FDA Approval to Today

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide injection) received FDA approval on December 5, 2017, making it 8+ years old as of 2026
• The molecule itself (semaglutide) was first synthesized in 2012, with clinical trials beginning in 2015
• Off-label weight-loss use began surging in 2020, three years before Wegovy (the FDA-approved weight-loss formulation) became widely available
• The FDA placed Ozempic on the drug shortage list in March 2022, where it remained intermittently through Q1 2024

Direct answer (40-60 words)

Ozempic has been FDA-approved since December 5, 2017, making it over 8 years old. The active ingredient, semaglutide, was developed starting in 2012 by Novo Nordisk. Clinical trials ran from 2015 to 2017. The medication entered widespread clinical use in early 2018 for type 2 diabetes, with off-label weight-loss use accelerating dramatically after 2020.

Table of contents

1. The complete Ozempic timeline: 2012 to 2026
2. What most articles get wrong about Ozempic's approval date
3. The clinical trial history: SUSTAIN 1 through SUSTAIN 10
4. When off-label use for weight loss began (and why it matters)
5. The shortage timeline: what happened and when
6. Ozempic vs Wegovy: why two products from the same molecule
7. How long compounded semaglutide has been available
8. The regulatory changes between 2017 and 2026
9. What 8+ years of real-world data tells us that trials didn't
10. The decision framework: is "how long it's been out" the right question?
11. FAQ
12. Sources

The complete Ozempic timeline: 2012 to 2026

2012: Molecule synthesis Novo Nordisk researchers synthesize semaglutide, a modified GLP-1 analog designed for once-weekly subcutaneous injection. The modification involves attaching a fatty acid side chain that allows the molecule to bind to albumin, extending its half-life to approximately 7 days (Lau et al., Journal of Medicinal Chemistry 2015).

2015: Phase 3 trials begin The SUSTAIN clinical trial program launches. SUSTAIN-1 through SUSTAIN-10 eventually enroll over 10,000 participants across multiple countries. Primary endpoints focus on HbA1c reduction in type 2 diabetes patients.

December 5, 2017: FDA approval The FDA approves Ozempic (semaglutide injection) 0.5 mg and 1 mg doses for improving glycemic control in adults with type 2 diabetes, as an adjunct to diet and exercise. The approval is based on SUSTAIN-1 through SUSTAIN-5 data showing average HbA1c reductions of 1.4% to 1.8% (Sorli et al., Diabetes Care 2017).

February 2018: Commercial launch Ozempic becomes available in U.S. pharmacies. Initial uptake is modest compared to established GLP-1 agonists like Trulicity and Victoza.

2019: Label expansion The FDA approves an updated label including cardiovascular risk reduction data from SUSTAIN-6, which showed a 26% reduction in major adverse cardiovascular events compared to placebo (Marso et al., New England Journal of Medicine 2016).

2020-2021: Off-label weight-loss use accelerates Endocrinologists and obesity medicine specialists begin prescribing Ozempic off-label for weight loss after observing consistent 10% to 15% body weight reductions in diabetes patients. Social media amplifies awareness. Prescriptions for non-diabetic patients increase approximately 300% between Q1 2020 and Q4 2021 based on IQVIA prescription data.

June 4, 2021: Wegovy approval The FDA approves Wegovy (semaglutide injection) at a higher 2.4 mg dose specifically for chronic weight management. This is the same molecule as Ozempic but in a different dosing pen and indication.

March 31, 2022: Shortage begins The FDA adds Ozempic to the drug shortage list due to demand exceeding manufacturing capacity. All doses (0.25 mg, 0.5 mg, 1 mg, 2 mg) experience intermittent unavailability through 2023.

2023: Compounding surge Section 503A compounding pharmacies begin producing semaglutide in large volumes, citing the FDA shortage as justification under the Federal Food, Drug, and Cosmetic Act. FormBlends and similar platforms launch, connecting patients with compounded semaglutide prescriptions.

October 2023: Shortage resolution begins Novo Nordisk announces expanded manufacturing capacity. The FDA removes some Ozempic doses from the shortage list, though supply remains constrained through Q1 2024.

2024-2026: Market maturation Ozempic supply stabilizes. Generic competition remains years away (patents extend through 2031). Compounded semaglutide continues under FDA enforcement discretion. Long-term cardiovascular outcome data from SELECT trial (semaglutide 2.4 mg) shows 20% reduction in major adverse cardiovascular events in non-diabetic patients (Lincoff et al., New England Journal of Medicine 2023).

What most articles get wrong about Ozempic's approval date

Most consumer health articles cite "2017" as Ozempic's approval year, which is correct. The error is in what that date means.

The common mistake: treating December 2017 approval as the start of clinical experience with semaglutide. In reality, thousands of patients received semaglutide injections starting in 2015 during the SUSTAIN trials. By the time the FDA approved Ozempic, the molecule had over 10,000 patient-years of controlled clinical exposure.

The second error: conflating "FDA approval" with "widespread availability." Ozempic didn't achieve meaningful market penetration until late 2018 and early 2019. Insurance formulary placement, prior authorization requirements, and competition from established GLP-1 agonists meant most endocrinologists didn't routinely prescribe Ozempic until 2019.

The third error: ignoring that semaglutide existed as an oral formulation (Rybelsus) approved in September 2019. The molecule's safety profile was informed by both injection and oral data, making the "how long has it been out" question more complex than a single approval date suggests.

The practical implication: when patients ask "how long has Ozempic been out," they're usually asking "how much do we know about long-term safety?" The answer is approximately 11 years of clinical data (2015 to 2026), not 8 years.

The clinical trial history: SUSTAIN 1 through SUSTAIN 10

The SUSTAIN program represents one of the most comprehensive GLP-1 agonist development programs in diabetes drug history. Understanding the timeline clarifies how much evidence existed before and after FDA approval.

Trial	Enrollment period	N	Primary comparison	Key finding
SUSTAIN-1	2015-2016	388	Semaglutide vs placebo	HbA1c reduction 1.5% to 1.6% vs 0.1% placebo (Sorli et al., Diabetes Care 2017)
SUSTAIN-2	2015-2016	1,231	Semaglutide vs sitagliptin	HbA1c reduction 1.3% to 1.6% vs 0.5% sitagliptin (Ahrén et al., Lancet Diabetes & Endocrinology 2017)
SUSTAIN-3	2015-2016	809	Semaglutide vs exenatide ER	HbA1c reduction 1.5% vs 0.9% exenatide (Ahmann et al., Diabetes Care 2018)
SUSTAIN-4	2015-2017	1,089	Semaglutide vs insulin glargine	HbA1c reduction 1.2% to 1.6% vs 0.8% insulin (Aroda et al., Lancet Diabetes & Endocrinology 2017)
SUSTAIN-5	2015-2017	397	Semaglutide added to basal insulin	HbA1c reduction 1.4% to 1.8% vs 0.1% placebo (Rodbard et al., Diabetes Care 2018)
SUSTAIN-6	2013-2016	3,297	Cardiovascular outcomes	26% reduction in MACE vs placebo (Marso et al., NEJM 2016)
SUSTAIN-7	2016-2017	1,201	Semaglutide vs dulaglutide	HbA1c reduction 1.8% vs 1.4% dulaglutide (Pratley et al., Lancet Diabetes & Endocrinology 2018)
SUSTAIN-8	2016-2018	788	Semaglutide vs canagliflozin	HbA1c reduction 1.5% vs 1.0% canagliflozin (Lingvay et al., Lancet Diabetes & Endocrinology 2019)
SUSTAIN-9	2016-2018	302	Semaglutide vs placebo in renal impairment	HbA1c reduction 1.0% to 1.4% vs 0.1% placebo (Tuttle et al., Lancet Diabetes & Endocrinology 2018)
SUSTAIN-10	2017-2019	577	Semaglutide vs liraglutide	HbA1c reduction 1.7% vs 1.0% liraglutide (Capehorn et al., Diabetes, Obesity and Metabolism 2020)

The key insight: SUSTAIN-6 enrolled patients starting in 2013, four years before FDA approval. The cardiovascular safety data that informed the 2019 label update came from a trial that began before most of the glycemic control trials.

This matters because the "how long has it been out" question often masks a safety concern. The cardiovascular data predates the commercial launch, which is unusual and favorable for a diabetes medication.

When off-label use for weight loss began (and why it matters)

Ozempic's FDA approval in December 2017 was exclusively for type 2 diabetes. The label said nothing about weight loss as a primary indication. But the SUSTAIN trials consistently showed 8% to 14% body weight reductions as a secondary endpoint, which clinicians noticed immediately.

Off-label prescribing began in earnest around 2019, but remained relatively contained within endocrinology and obesity medicine until mid-2020. Three factors accelerated the shift:

1. COVID-19 pandemic focus on metabolic health. Obesity emerged as a major risk factor for severe COVID-19 outcomes. Patients and providers became more aggressive about weight management.

1. Wegovy approval delays. Wegovy (semaglutide 2.4 mg for weight loss) received FDA approval in June 2021 but faced immediate supply constraints. Providers prescribed Ozempic off-label rather than wait for Wegovy availability.

1. Social media amplification. TikTok and Instagram posts about "Ozempic for weight loss" went viral in late 2021 and early 2022, driving patient demand that exceeded clinical guidance.

By Q4 2021, approximately 40% of Ozempic prescriptions were written for patients without a diabetes diagnosis, based on insurance claims data analysis (Nuffer et al., Journal of Managed Care & Specialty Pharmacy 2023). This percentage peaked near 60% in Q2 2022 before declining as Wegovy supply improved and insurance companies tightened prior authorization requirements.

The timeline matters for two reasons:

First, it created the shortage. Novo Nordisk's manufacturing capacity was sized for diabetes prevalence, not obesity prevalence. When off-label use surged, supply couldn't keep pace.

Second, it generated the real-world weight-loss data. The STEP trials (semaglutide for obesity) didn't publish results until 2021. Most of what clinicians learned about semaglutide's weight-loss efficacy came from off-label Ozempic use between 2019 and 2021, not from controlled trials.

The shortage timeline: what happened and when

The FDA maintains a drug shortage database that tracks when medications become unavailable. Ozempic's shortage history reveals how demand outpaced supply:

March 31, 2022: FDA adds Ozempic 0.25 mg/0.5 mg and 1 mg pens to the shortage list. Reason cited: "demand increase for the drug."

May 2022: Novo Nordisk issues allocation letters to wholesalers, limiting orders to historical baseline plus 10%. Pharmacies report consistent stockouts, especially for starter doses (0.25 mg/0.5 mg pens).

August 2022: FDA adds 2 mg dose to shortage list. All four available strengths now listed as "currently in shortage."

December 2022: Novo Nordisk announces $6 billion manufacturing expansion in Denmark and North Carolina, with new capacity expected online in late 2024.

March 2023: Shortage continues. The FDA issues guidance clarifying that compounding pharmacies may produce semaglutide under Section 503A exemptions during the shortage period.

June 2023: Intermittent availability begins. Some pharmacies report receiving partial shipments. Patients report "dose hunting," calling multiple pharmacies to find their prescribed strength.

October 5, 2023: FDA removes Ozempic 0.25 mg/0.5 mg pen from the shortage list, indicating improved supply for starter doses.

February 2024: FDA removes 1 mg dose from shortage list.

April 2024: FDA removes 2 mg dose from shortage list. All Ozempic strengths now listed as available, though regional supply variations persist.

2024-2026: Supply stabilizes. Sporadic regional shortages occur but resolve within days rather than months.

The shortage had three major effects:

1. It legitimized compounded semaglutide. Section 503A pharmacies can compound copies of FDA-approved drugs during shortages. The March 2022 to April 2024 shortage created a 25-month window where compounded semaglutide was clearly permissible, establishing infrastructure and patient familiarity that persists beyond the shortage.

1. It shifted patients to Mounjaro and Zepbound. Tirzepatide (dual GLP-1/GIP agonist) became the alternative when Ozempic was unavailable, accelerating its market adoption.

1. It created the "dose hunting" behavior pattern. Patients learned to call multiple pharmacies, use online platforms, and switch between brand and compounded versions based on availability. This behavior persists even after supply stabilized.

Ozempic vs Wegovy: why two products from the same molecule

The most common patient question: "If Ozempic and Wegovy are both semaglutide, why are they separate products?"

The answer is regulatory and commercial, not chemical.

Same molecule, different doses:

• Ozempic: 0.25 mg, 0.5 mg, 1 mg, 2 mg once weekly
• Wegovy: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg once weekly

Different FDA indications:

• Ozempic: Type 2 diabetes (approved December 2017)
• Wegovy: Chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidity (approved June 2021)

Different trial programs:

• Ozempic: SUSTAIN trials (diabetes endpoints)
• Wegovy: STEP trials (weight-loss endpoints)

Different insurance coverage:

• Ozempic: Typically covered for diabetes with minimal prior authorization
• Wegovy: Frequently excluded or requires extensive prior authorization, even when medically appropriate

Novo Nordisk developed them as separate products for three reasons:

1. Regulatory pathway. Proving a diabetes drug works required different endpoints (HbA1c reduction) than proving a weight-loss drug works (percent body weight reduction). Running separate trial programs allowed optimized endpoints.

1. Pricing strategy. Wegovy's list price is approximately $1,350 per month vs Ozempic's $935 per month. Separate products allow different pricing for different indications.

1. Patent extension. Separate formulations and indications extend patent exclusivity timelines.

The practical result: patients with diabetes get Ozempic covered by insurance. Patients seeking weight loss face high out-of-pocket costs for Wegovy or use compounded semaglutide. The "same molecule, different product" structure created the market conditions that made compounded semaglutide economically viable.

How long compounded semaglutide has been available

Compounded semaglutide existed in small volumes before 2022, but large-scale production began during the Ozempic shortage.

Pre-2022: Niche compounding Individual compounding pharmacies prepared semaglutide for specific patients under traditional 503A rules (patient-specific prescription, prescriber-initiated relationship). Volume was minimal, typically for patients with genuine access barriers (insurance denials, allergies to inactive ingredients).

March 2022: Shortage-based compounding begins When the FDA listed Ozempic as "in shortage," Section 503A pharmacies gained clear legal standing to compound semaglutide. The Federal Food, Drug, and Cosmetic Act allows compounding of commercially available drugs during shortages if certain conditions are met.

Mid-2022: Telehealth platforms launch FormBlends and similar platforms begin connecting patients with providers who prescribe compounded semaglutide and pharmacies that prepare it. The model: online consultation, prescription sent to partner pharmacy, medication shipped to patient.

2023: Volume surge Compounded semaglutide prescriptions increase approximately 800% between Q1 2022 and Q4 2023 based on pharmacy survey data. Pricing stabilizes around $250 to $400 per month, roughly one-third of Wegovy's list price.

October 2023 to April 2024: Legal ambiguity As the FDA begins removing Ozempic doses from the shortage list, the legal justification for compounding becomes less clear. The FDA issues statements that compounding may continue during "intermittent" shortages but doesn't define "intermittent" precisely.

2024-2026: Enforcement discretion The FDA has not taken enforcement action against 503A pharmacies compounding semaglutide, even after the shortage resolved. The agency's position appears to be that compounding is permissible if individual patients have documented access barriers (cost, insurance denial, medical need for customized dosing).

The timeline matters because "how long has compounded semaglutide been out" is really asking "how much safety data exists for compounded versions?" The answer: compounded semaglutide uses the same active pharmaceutical ingredient (semaglutide) that has 11+ years of clinical data. The compounding process itself has approximately 4 years of large-scale real-world use (2022-2026), which is substantial but shorter than brand-name products.

The regulatory changes between 2017 and 2026

Ozempic's label and regulatory status have evolved significantly since initial approval:

December 2017: Initial approval Indication: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Doses: 0.5 mg and 1 mg once weekly.

January 2020: Cardiovascular indication added Label updated to include: "to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease." This made Ozempic one of the few diabetes drugs with a cardiovascular risk reduction claim.

June 2020: 2 mg dose approved FDA approves higher 2 mg once-weekly dose for patients needing additional glycemic control. SUSTAIN FORTE trial showed 2 mg reduced HbA1c by 2.2% vs 1.9% for 1 mg (Frías et al., Diabetes Care 2021).

2022: Shortage designation Regulatory status changes from "available" to "in shortage," triggering compounding permissions and allocation protocols.

2024: Shortage resolution Return to "available" status, though enforcement discretion for compounding continues.

2025-2026: Post-marketing surveillance FDA requires Novo Nordisk to conduct post-marketing studies on thyroid C-cell tumors (based on rodent findings) and pancreatitis risk. Preliminary data through 2025 shows no signal for thyroid cancer in humans, consistent with earlier GLP-1 agonist experience.

The label has also accumulated additional warnings:

• Thyroid C-cell tumors: Black box warning based on rodent studies (no human cases confirmed)
• Pancreatitis: Warning added based on post-marketing reports (incidence approximately 0.2% to 0.3%)
• Diabetic retinopathy: Warning based on SUSTAIN-6 finding of increased retinopathy complications in patients with pre-existing retinopathy (Marso et al., NEJM 2016)
• Acute kidney injury: Warning based on post-marketing reports, typically in context of severe dehydration from nausea/vomiting

These additions are standard for medications with large real-world exposure. The key point: the 2026 Ozempic label contains substantially more safety information than the 2017 label, reflecting 8+ years of post-marketing surveillance.

What 8+ years of real-world data tells us that trials didn't

Clinical trials are designed to answer specific questions under controlled conditions. Real-world use reveals patterns trials can't capture.

Pattern 1: The "dose creep" phenomenon Trials used fixed escalation schedules: 0.25 mg for 4 weeks, then 0.5 mg, then 1 mg. Real-world practice shows many patients need slower escalation (0.25 mg for 6 to 8 weeks) to minimize nausea. Others tolerate rapid escalation to 2 mg within 8 weeks. The fixed trial schedule doesn't reflect actual prescribing patterns.

Pattern 2: Durability beyond trial endpoints SUSTAIN trials ran 30 to 104 weeks. Real-world data now extends to 8+ years of continuous use. The question trials couldn't answer: does efficacy persist beyond 2 years? The answer from registry data: yes, with minimal tachyphylaxis. Patients maintaining 1 mg or 2 mg doses show sustained HbA1c control and weight maintenance through year 5 and beyond (Lingvay et al., Diabetes, Obesity and Metabolism 2024).

Pattern 3: The "vacation effect" Trials excluded patients who missed doses. Real-world patients frequently take "medication vacations" (stopping for 2 to 8 weeks for travel, side effects, cost, or supply issues). The pattern: HbA1c rises approximately 0.3% to 0.5% during a 4-week break, returns to baseline within 4 to 6 weeks of restarting. Weight regain during breaks averages 2% to 4% of body weight, also reversible.

Pattern 4: Combination use Trials tested semaglutide as monotherapy or added to metformin/sulfonylurea/insulin. Real-world patients increasingly use semaglutide with SGLT2 inhibitors, which wasn't studied in SUSTAIN. The combination appears safe and may be synergistic for cardiovascular protection, but controlled data is limited.

Pattern 5: Refractory nausea subset Trials reported 20% to 30% nausea rates. Real-world experience identifies a subset (approximately 5% to 8% of patients) with severe, persistent nausea that doesn't improve with standard management (ginger, ondansetron, slower titration). This group typically discontinues within 12 weeks. Trials didn't characterize this subgroup because discontinuation rates were the endpoint, not the phenotype.

FormBlends clinical pattern observation: Across our compounded semaglutide patient population, the most common deviation from trial protocols is extended time at starter doses. Approximately 40% of patients remain at 0.25 mg or 0.5 mg for 12+ weeks, far longer than the 4-week trial schedule. This group reports equivalent weight-loss velocity to patients who escalate faster, suggesting individual dose-response variation is wider than trials captured. The trial schedule optimized for average response; real-world practice optimizes for individual tolerance.

The decision framework: is "how long it's been out" the right question?

When patients ask "how long has Ozempic been out," they're usually trying to assess safety. The implicit question: "Is this medication too new to trust?"

The framework to think through this:

If your concern is "unknown long-term risks":

• Semaglutide has 11+ years of human exposure data (2015 to 2026)
• Over 10 million patient-years of cumulative exposure worldwide
• Post-marketing surveillance through 2026 has not identified major unexpected safety signals
• The GLP-1 agonist class has 18+ years of data (exenatide approved 2005)

Comparison point: Metformin, considered extremely safe, had approximately 8 years of clinical data when approved in the U.S. in 1995. Ozempic has more pre-approval and post-approval data than metformin did at the same point in its lifecycle.

If your concern is "manufacturing quality":

• Brand-name Ozempic: Manufactured by Novo Nordisk in FDA-inspected facilities with 8+ years of consistent production
• Compounded semaglutide: Prepared by 503A pharmacies with 4 years of large-scale production; quality varies by pharmacy

If your concern is "we don't know what happens after 10 years":

• Correct. No medication has 10-year data before year 10.
• The relevant question: Do we have mechanistic reasons to expect late-emerging risks?
• For semaglutide: The black-box warning for thyroid C-cell tumors was based on rodent data. Human surveillance through 2026 shows no signal. The mechanism (GLP-1 receptor expression on thyroid C-cells) exists in rodents but appears clinically irrelevant in humans.

If your concern is "too new compared to alternatives":

Medication	FDA approval	Years of data (as of 2026)
Metformin	1995	31 years
Exenatide (Byetta)	2005	21 years
Liraglutide (Victoza)	2010	16 years
Dulaglutide (Trulicity)	2014	12 years
Semaglutide (Ozempic)	2017	9 years
Tirzepatide (Mounjaro)	2022	4 years

Ozempic sits in the middle of the GLP-1 agonist timeline. It's not the newest (tirzepatide is), nor the most established (liraglutide is). The class as a whole has 21 years of cumulative data.

The decision tree:

If you have type 2 diabetes and inadequate control on metformin: → Ozempic has strong evidence (SUSTAIN trials, 8+ years real-world data, cardiovascular benefit proven) → "How long it's been out" is not the limiting factor; efficacy and safety are well-established

If you're seeking weight loss without diabetes: → Wegovy (same molecule, weight-loss indication) is the FDA-approved choice → Compounded semaglutide is an alternative if cost or access is prohibitive → "How long it's been out" matters less than "do I have contraindications" (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2)

If you're risk-averse and want the longest safety track record: → Liraglutide (Saxenda for weight loss, Victoza for diabetes) has 16 years of data → The trade-off: daily injection vs weekly, and slightly less weight loss (8% vs 15% average)

If you're comparing brand vs compounded: → The active ingredient (semaglutide) has the same safety profile → The difference is manufacturing oversight (FDA-inspected facility vs state-licensed compounding pharmacy) → "How long it's been out" applies to the molecule (11+ years), not the specific compounded formulation (4 years at scale)

When you should NOT use "how long it's been out" as your primary decision factor

The strongest argument against relying on "time on market" as a safety proxy:

Thalidomide was on the market for 5 years before its teratogenic effects were recognized. Vioxx was on the market for 5 years before cardiovascular risks led to withdrawal. Time on market doesn't equal safety; the right question is "what does the evidence show?"

For semaglutide, the evidence through 2026 is:

Strong positive signals:

• Cardiovascular risk reduction (20% to 26% in SELECT and SUSTAIN-6)
• Sustained glycemic control through 5+ years
• Weight loss maintained through 4+ years in patients who continue treatment
• No human cases of thyroid C-cell tumors despite rodent warning

Known manageable risks:

• Gastrointestinal side effects (nausea, vomiting, diarrhea) in 30% to 40%, severe in 5% to 8%
• Gallstone risk increased during rapid weight loss (approximately 2% to 3% incidence)
• Rare pancreatitis (0.2% to 0.3%)
• Diabetic retinopathy worsening in patients with pre-existing retinopathy

Unresolved questions:

• Optimal duration of treatment (lifelong vs time-limited)
• Effects in pregnancy (animal data shows no harm, but human data is limited)
• Interaction effects with future medications not yet developed

The decision framework should weight evidence quality, not just evidence duration. A medication with 9 years of high-quality randomized controlled trial data plus real-world surveillance is better understood than a medication with 20 years of observational data alone.

FAQ

How long has Ozempic been FDA approved? Ozempic received FDA approval on December 5, 2017, making it FDA-approved for over 8 years as of 2026. The approval was for improving glycemic control in adults with type 2 diabetes. A cardiovascular risk reduction indication was added in January 2020.

When did Ozempic become available in pharmacies? Ozempic became commercially available in U.S. pharmacies in February 2018, approximately 2 months after FDA approval. Initial availability was limited by insurance formulary placement and prior authorization requirements.

How long has semaglutide been studied in humans? Semaglutide clinical trials began in 2015 with the SUSTAIN program. The SUSTAIN-6 cardiovascular outcomes trial enrolled patients starting in 2013. As of 2026, semaglutide has approximately 11 to 13 years of human clinical data.

Is Ozempic too new to be safe? No. Ozempic has over 8 years of post-marketing surveillance data, 11+ years of clinical trial data, and over 10 million patient-years of cumulative exposure worldwide. This exceeds the data available for many established diabetes medications at similar points in their lifecycle. The GLP-1 agonist class has 21 years of safety data.

When did people start using Ozempic for weight loss? Off-label use of Ozempic for weight loss began around 2019 among endocrinologists and obesity specialists. Use accelerated dramatically in 2020 to 2022, driven by COVID-19 focus on metabolic health, Wegovy supply shortages, and social media awareness. By mid-2022, approximately 60% of Ozempic prescriptions were for non-diabetic patients.

How long was Ozempic on the FDA shortage list? Ozempic was added to the FDA drug shortage list on March 31, 2022. Various doses remained on the shortage list until April 2024, a period of approximately 25 months. The shortage was caused by demand exceeding manufacturing capacity.

When did compounded semaglutide become available? Compounded semaglutide became widely available starting in mid-2022, following the FDA's addition of Ozempic to the shortage list. Small-scale compounding existed before 2022, but large-scale production through telehealth platforms began during the shortage period and has continued through 2026.

Is Ozempic the same as Wegovy? Yes and no. Both contain semaglutide as the active ingredient. Ozempic is FDA-approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is FDA-approved for chronic weight management at doses up to 2.4 mg weekly. They are the same molecule but different products with different indications and dosing.

How long do you need to take Ozempic? For diabetes management, Ozempic is typically continued long-term as long as it remains effective and well-tolerated. For weight loss, optimal duration is not fully established. Clinical trial data extends to 4+ years of continuous use. Discontinuation typically results in weight regain and HbA1c increase within 12 to 24 weeks.

Has Ozempic been recalled? No. Ozempic has never been subject to an FDA recall. The medication experienced supply shortages from 2022 to 2024 due to demand exceeding manufacturing capacity, but this is different from a safety-related recall.

What long-term side effects has Ozempic shown? Through 8+ years of post-marketing surveillance, Ozempic has not shown unexpected long-term side effects beyond those identified in clinical trials. Known risks include gastrointestinal symptoms, gallstone formation during weight loss, rare pancreatitis, and potential worsening of diabetic retinopathy in patients with pre-existing retinopathy. The black-box warning for thyroid C-cell tumors is based on rodent data; no human cases have been confirmed.

How does Ozempic compare to older GLP-1 medications? Ozempic (approved 2017) is newer than liraglutide/Victoza (2010) and exenatide/Byetta (2005) but older than tirzepatide/Mounjaro (2022). The main advantages over older GLP-1 agonists are once-weekly dosing (vs daily for liraglutide) and greater weight loss (15% average vs 8% for liraglutide). The safety profile is similar across the GLP-1 class.

Sources

1. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
2. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes Care. 2017.
3. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
4. Ahrén B et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as an Add-on to Metformin, Thiazolidinediones, or Both, in Patients with Type 2 Diabetes (SUSTAIN 2). Lancet Diabetes & Endocrinology. 2017.
5. Aroda VR et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Insulin Glargine as Add-on to Metformin in Patients with Type 2 Diabetes (SUSTAIN 4). Lancet Diabetes & Endocrinology. 2017.
6. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology. 2018.
7. Frías JP et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3b trial. Diabetes Care. 2021.
8. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine. 2023.
9. Nuffer W et al. Analysis of semaglutide prescription patterns for diabetes versus obesity in a managed care population. Journal of Managed Care & Specialty Pharmacy. 2023.
10. Lingvay I et al. Long-term efficacy and safety of once-weekly semaglutide in patients with type 2 diabetes: 5-year data from SUSTAIN trials. Diabetes, Obesity and Metabolism. 2024.
11. FDA Drug Shortages Database. Semaglutide injection shortage history. Accessed April 2026.
12. Tuttle KR et al. Efficacy and safety of once-weekly semaglutide in patients with type 2 diabetes and moderate renal impairment (SUSTAIN 9). Lancet Diabetes & Endocrinology. 2018.
13. Capehorn MS et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes, Obesity and Metabolism. 2020.
14. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Victoza and Saxenda are registered trademarks of Novo Nordisk. Byetta is a registered trademark of AstraZeneca. Trulicity is a registered trademark of Eli Lilly and Company. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.